D-JNKI-1

Additional information:
D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK.|Product information|CAS Number: 1445179-97-4|Molecular Weight: 3822.44|Formula: C164H286N66O40|Chemical Name: (3R)-3-amino-3-{[(1R)-1-{[(1R)-1-{[(2R)-1-[(2R)-2-{[(1R)-1-{[(2R)-1-[(2R)-2-{[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R,2S)-1-{[(2R,3S)-1-[(2R)-2-{[(1R)-1-{[(2R)-6-amino-1-[(2R)-2-{[(2R)-1-[(2R)-2-[(2R)-2-{[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R)-1-{[(1R)-5-amino-1-{[(1R)-5-amino-1-{[(1R)-4-carbamimidamido-1-[(carbamoylmethyl)carbamoyl]butyl]carbamoyl}pentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]carbamoyl}-2-hydroxypropyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-carbamoylethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-phenylethyl]carbamoyl}pyrrolidin-1-yl]-4-carbamoyl-1-oxobutan-2-yl]carbamoyl}-2-methylpropyl]carbamoyl}pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl}-2-hydroxyethyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}propanoic acid|Smiles: C[C@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC1C=CC=CC=1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(O)=O)C(C)C)C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O|InChiKey: BAAXVYBAMNDCIB-BMCUWHFPSA-N|InChi: InChI=1S/C164H286N66O40/c1-84(2)77-106(217-139(254)108(79-89-33-10-9-11-34-89)220-146(261)112-48-28-72-226(112)153(268)105(55-58-119(171)236)216-148(263)123(86(5)6)222-147(262)115-51-29-73-227(115)151(266)103(45-25-69-199-163(188)189)214-142(257)110(83-231)221-137(252)100(53-56-117(169)234)202-126(241)90(168)80-122(239)240)138(253)219-109(81-120(172)237)140(255)218-107(78-85(3)4)141(256)223-124(87(7)232)149(264)224-125(88(8)233)155(270)229-75-31-50-114(229)144(259)212-99(44-24-68-198-162(186)187)135(250)213-102(37-14-17-61-167)150(265)225-71-27-47-111(225)145(260)215-104(46-26-70-200-164(190)191)152(267)230-76-32-52-116(230)154(269)228-74-30-49-113(228)143(258)211-98(43-23-67-197-161(184)185)134(249)208-95(40-20-64-194-158(178)179)131(246)207-97(42-22-66-196-160(182)183)133(248)210-101(54-57-118(170)235)136(251)209-96(41-21-65-195-159(180)181)132(247)206-94(39-19-63-193-157(176)177)130(245)205-93(36-13-16-60-166)129(244)204-92(35-12-15-59-165)128(243)203-91(38-18-62-192-156(174)175)127(242)201-82-121(173)238/h9-11,33-34,84-88,90-116,123-125,231-233H,12-32,35-83,165-168H2,1-8H3,(H2,169,234)(H2,170,235)(H2,171,236)(H2,172,237)(H2,173,238)(H,201,242)(H,202,241)(H,203,243)(H,204,244)(H,205,245)(H,206,247)(H,207,246)(H,208,249)(H,209,251)(H,210,248)(H,211,258)(H,212,259)(H,213,250)(H,214,257)(H,215,260)(H,216,263)(H,217,254)(H,218,255)(H,219,253)(H,220,261)(H,221,252)(H,222,262)(H,223,256)(H,224,264)(H,239,240)(H4,174,175,192)(H4,176,177,193)(H4,178,179,194)(H4,180,181,195)(H4,182,183,196)(H4,184,185,197)(H4,186,187,198)(H4,188,189,199)(H4,190,191,200)/t87-,88-,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,123+,124+,125+/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (26.{{Nociceptin} medchemexpress|{Nociceptin} GPCR/G Protein|{Nociceptin} Protocol|{Nociceptin} Description|{Nociceptin} custom synthesis|{Nociceptin} Epigenetics} 16 mM).{{Aurothioglucose} site|{Aurothioglucose} Metabolic Enzyme/Protease|{Aurothioglucose} Immunology/Inflammation|{Aurothioglucose} Protocol|{Aurothioglucose} In stock|{Aurothioglucose} manufacturer} H2O : ≥ 50 mg/mL (13.PMID:24761411 08 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|D-JNKI-1 (AM-111; 1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells.|In Vivo:|D-JNKI-1 (AM-111; 10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+ and CD8+ cells in mice.|Products are for research use only. Not for human use.|